- Home
- AARD vs NKTR Comparison
AARD vs NKTR Comparison
Compare AARD & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- NKTR
- Stock Information
- Founded
- AARD 2017
- NKTR 1990
- Country
- AARD United States
- NKTR United States
- Employees
- AARD N/A
- NKTR N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- AARD Health Care
- NKTR Health Care
- Exchange
- AARD Nasdaq
- NKTR Nasdaq
- Market Cap
- AARD 154.9M
- NKTR 160.4M
- IPO Year
- AARD 2025
- NKTR 1994
- Fundamental
- Price
- AARD $10.14
- NKTR $0.71
- Analyst Decision
- AARD Strong Buy
- NKTR Strong Buy
- Analyst Count
- AARD 4
- NKTR 6
- Target Price
- AARD $31.50
- NKTR $4.92
- AVG Volume (30 Days)
- AARD 69.4K
- NKTR 2.1M
- Earning Date
- AARD 01-01-0001
- NKTR 05-08-2025
- Dividend Yield
- AARD N/A
- NKTR N/A
- EPS Growth
- AARD N/A
- NKTR N/A
- EPS
- AARD N/A
- NKTR N/A
- Revenue
- AARD N/A
- NKTR $87,248,000.00
- Revenue This Year
- AARD N/A
- NKTR N/A
- Revenue Next Year
- AARD N/A
- NKTR N/A
- P/E Ratio
- AARD N/A
- NKTR N/A
- Revenue Growth
- AARD N/A
- NKTR N/A
- 52 Week Low
- AARD $4.88
- NKTR $0.43
- 52 Week High
- AARD $19.58
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- NKTR 52.22
- Support Level
- AARD N/A
- NKTR $0.71
- Resistance Level
- AARD N/A
- NKTR $0.81
- Average True Range (ATR)
- AARD 0.00
- NKTR 0.07
- MACD
- AARD 0.00
- NKTR 0.00
- Stochastic Oscillator
- AARD 0.00
- NKTR 56.00
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.